vs
Pioneer Bancorp, Inc.（PBFS）与ARS Pharmaceuticals, Inc.（SPRY）财务数据对比。点击上方公司名可切换其他公司
ARS Pharmaceuticals, Inc.的季度营收约是Pioneer Bancorp, Inc.的1.1倍（$28.1M vs $25.0M），Pioneer Bancorp, Inc.净利率更高（82.1% vs -147.1%，领先229.2%）
先锋银行控股公司（马里兰州）是一家美国银行控股企业，为先锋银行的母公司，主要面向马里兰州本地社区用户提供零售及商业银行服务，涵盖存款账户、住房与商业抵押贷款、消费贷款及小微企业融资等产品。
ARS Pharmaceuticals是一家处于后期研发阶段的生物制药企业，专注于开发和商业化严重过敏反应创新疗法，核心产品为无需注射的肾上腺素鼻腔递送制剂，主要面向北美市场，服务存在致命过敏风险的成人及儿童患者群体。
PBFS vs SPRY — 直观对比
营收规模更大
SPRY
是对方的1.1倍
$25.0M
净利率更高
PBFS
高出229.2%
-147.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.0M | $28.1M |
| 净利润 | $3.7M | $-41.3M |
| 毛利率 | — | — |
| 营业利润率 | 21.3% | -147.6% |
| 净利率 | 82.1% | -147.1% |
| 营收同比 | — | -67.6% |
| 净利润同比 | — | -182.8% |
| 每股收益（稀释后） | $0.16 | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBFSSPRY
| Q4 25 | $25.0M | $28.1M | ||
| Q3 25 | $24.0M | $32.5M | ||
| Q2 25 | $24.4M | $15.7M | ||
| Q1 25 | $22.8M | $8.0M | ||
| Q4 24 | — | $86.6M | ||
| Q3 24 | $22.0M | $2.1M | ||
| Q2 24 | $20.9M | $500.0K | ||
| Q1 24 | $21.6M | $0 |
净利润PBFSSPRY
| Q4 25 | $3.7M | $-41.3M | ||
| Q3 25 | $4.3M | $-51.2M | ||
| Q2 25 | $6.5M | $-44.9M | ||
| Q1 25 | $5.8M | $-33.9M | ||
| Q4 24 | — | $49.9M | ||
| Q3 24 | $6.3M | $-19.1M | ||
| Q2 24 | $3.9M | $-12.5M | ||
| Q1 24 | $4.7M | $-10.3M |
营业利润率PBFSSPRY
| Q4 25 | 21.3% | -147.6% | ||
| Q3 25 | 23.4% | -163.7% | ||
| Q2 25 | 33.3% | -302.9% | ||
| Q1 25 | 32.5% | -466.3% | ||
| Q4 24 | — | 54.5% | ||
| Q3 24 | 37.2% | -1051.6% | ||
| Q2 24 | 24.1% | -3068.0% | ||
| Q1 24 | 28.1% | — |
净利率PBFSSPRY
| Q4 25 | 82.1% | -147.1% | ||
| Q3 25 | 18.0% | -157.4% | ||
| Q2 25 | 26.4% | -285.6% | ||
| Q1 25 | 25.3% | -425.7% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | 28.7% | -925.0% | ||
| Q2 24 | 107.4% | -2503.2% | ||
| Q1 24 | 21.9% | — |
每股收益（稀释后）PBFSSPRY
| Q4 25 | $0.16 | $-0.41 | ||
| Q3 25 | $0.18 | $-0.52 | ||
| Q2 25 | $0.26 | $-0.46 | ||
| Q1 25 | $0.23 | $-0.35 | ||
| Q4 24 | — | $0.52 | ||
| Q3 24 | $0.25 | $-0.20 | ||
| Q2 24 | $0.15 | $-0.13 | ||
| Q1 24 | $0.19 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $245.0M |
| 总债务越低越好 | — | $96.4M |
| 股东权益账面价值 | $323.9M | $114.3M |
| 总资产 | $2.2B | $327.7M |
| 负债/权益比越低杠杆越低 | — | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资PBFSSPRY
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M | ||
| Q1 24 | — | $223.6M |
总债务PBFSSPRY
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PBFSSPRY
| Q4 25 | $323.9M | $114.3M | ||
| Q3 25 | $314.2M | $147.7M | ||
| Q2 25 | $314.2M | $192.3M | ||
| Q1 25 | $310.7M | $229.0M | ||
| Q4 24 | — | $256.8M | ||
| Q3 24 | $303.8M | $201.0M | ||
| Q2 24 | $296.5M | $215.2M | ||
| Q1 24 | $289.0M | $223.9M |
总资产PBFSSPRY
| Q4 25 | $2.2B | $327.7M | ||
| Q3 25 | $2.2B | $372.8M | ||
| Q2 25 | $2.1B | $313.5M | ||
| Q1 25 | $2.1B | $327.3M | ||
| Q4 24 | — | $351.2M | ||
| Q3 24 | $2.0B | $217.6M | ||
| Q2 24 | — | $222.0M | ||
| Q1 24 | $2.0B | $227.6M |
负债/权益比PBFSSPRY
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $11.1M | $-43.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | 2.97× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流PBFSSPRY
| Q4 25 | $11.1M | $-43.5M | ||
| Q3 25 | $3.9M | $-47.0M | ||
| Q2 25 | $5.1M | $-39.6M | ||
| Q1 25 | $-3.5M | $-40.7M | ||
| Q4 24 | — | $42.0M | ||
| Q3 24 | $1.9M | $-14.5M | ||
| Q2 24 | $9.0M | $-7.3M | ||
| Q1 24 | $3.3M | $-6.7M |
自由现金流PBFSSPRY
| Q4 25 | — | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.8M |
自由现金流率PBFSSPRY
| Q4 25 | — | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% | ||
| Q1 24 | — | — |
资本支出强度PBFSSPRY
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | — |
现金转化率PBFSSPRY
| Q4 25 | 2.97× | — | ||
| Q3 25 | 0.90× | — | ||
| Q2 25 | 0.78× | — | ||
| Q1 25 | -0.61× | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 2.30× | — | ||
| Q1 24 | 0.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBFS
暂无分部数据
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
